Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Adamis Pharmaceuticals’ Story is Delayed Another 12 to 18 Months – Still A “Buy”

Adamis Pharmaceuticals (NASDAQ:ADMP) received a new CRL from the FDA late last week. Here is company’s disclosure regarding the letter:

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company”) announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product.  PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction.   A CRL is issued by the FDA’s Center for Drug Evaluation and Research when it has completed its review of a file and questions remain that preclude the approval of the NDA in its current form.

Because of the improvements that were made to the PFS in response to the FDA’s original CRL dated March 27, 2015, the FDA indicated that in order to support approval of the product, the Company must expand its human factors study (patient usability) and reliability study (product stress testing), both of which were part of the final PFS NDA.  The Company believes that it can finalize the study protocols with the FDA and complete the additional testing within a relatively short period of time at an immaterial cost, and submit the data back to the FDA sometime in the second half of 2016.  It should be noted that the Company has successfully completed the “volume delivery” issue that was associated with the initial CRL.  The FDA has indicated that the NDA will remain open until these issues are resolved.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, “We look forward to working with the FDA to resolve the remaining issues. Our goal is to submit the protocols for these studies to the FDA within a matter of weeks and begin the testing as soon as we receive their feedback. We are confident that we can deliver all of the data requested by FDA and will continue to work closely with the agency to facilitate their continued review of our NDA. Adamis remains committed to bringing the epinephrine PFS to market.””

Prrefilled Syringe ADMP

Our analysis: We have been recommending Adamis to our premium subscribers since August 2014 when the shares were trading at $4.02. We also published a free report in April 2015 reiterating this recommendation. Adamis shares surged above $8 this year as the PDUFA date for its PFS NDA approached. We believed there is a 80-905 probability that the FDA would approve its product. After all this isn’t a new formulation, it is just a cheaper delivery mechanism of an existing formulation. Unfortunately for ADMP investors, FDA wants more testing before approving this product. This means ADMP will take another 6-12 months to gather the newly requested data points and FDA will take an additional 6 months to review and decide.

As a result of these delays, ADMP shares lost about 50% of its value. Currently it trades at $4.19. This price is consistent with ADMP’s price in November 2015 before it submitted its NDA. We believe ADMP’s stock price over the next 12 months will range between $3 and $6 depending on the performance of its recently acquired compounding business. If the company completes the additional studies, gathers the newly requested data, and submits it to the FDA by the end of this 12 month period, we will likely see an additional $4 increase in its stock price until the decision date. We maintain our view that FDA will eventually approve this low risk product.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!